Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbbVie (ABBV) is conducting a Phase 1 clinical study titled A Phase 1 First in Human, Single and Multiple Ascending Dose, Food Effect, and Drug-Drug Interaction Study in Healthy Volunteers to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABBV-CLS-616. The study aims to assess the safety and tolerability of the oral drug ABBV-CLS-616 in healthy adults, which could provide valuable insights into its potential therapeutic applications.
The intervention being tested is ABBV-CLS-616, an oral tablet, alongside a placebo and Itraconazole, an oral capsule. The study focuses on understanding the drug’s interactions and effects when administered in various conditions.
This interventional study is randomized with a parallel assignment model and triple masking involving participants, care providers, and investigators. Its primary purpose is basic science, aiming to gather foundational data on the drug’s safety and pharmacokinetics.
The study began on November 11, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on July 14, 2025, indicating ongoing recruitment and progress.
For investors, this study could influence AbbVie’s stock performance by potentially expanding its drug portfolio, enhancing its market position. The involvement of Calico Life Sciences LLC as a collaborator highlights the competitive landscape and strategic partnerships in the pharmaceutical industry.
The study is currently ongoing, with further details available on the ClinicalTrials portal.